Filtered By:
Cancer: Hepatocellular Carcinoma
This page shows you your search results in order of date.
Order by Relevance | Date
Total 1432 results found since Jan 2013.
Transcription Factor JunB Suppresses Hepatitis C Virus Replication
Kobe J Med Sci. 2023 Aug 31;69(3):E86-E95.ABSTRACTWe previously reported that hepatitis C virus (HCV) infection activates the reactive oxygen species (ROS)/c-Jun N-terminal kinase (JNK) signaling pathway. Activation of JNK contributes to the development of liver diseases, including metabolic disorders, steatosis, liver cirrhosis and hepatocellular carcinoma. JNK is known to have numerous target genes, including JunB, a member of activator protein-1 transcription factor family. However, the roles of JunB in the HCV life cycle and HCV-associated pathogenesis remain unclear. To clarify a physiological role of JunB in HCV infe...
Source: Kobe J Med Sci - September 4, 2023 Category: General Medicine Authors: Adi Ariffianto Lin Deng Saki Harada Yujiao Liang Chieko Matsui Takayuki Abe Ikuo Shoji Source Type: research
GSE197092 RNAseq analysis of genes differentially expressed in SMMC7721 cells with SNRPE knockdown
Contributors : Qipeng Wu ; Zhenzhou Jiang ; Luyong ZhangSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensHepatocellular carcinoma (HCC) is a malignant tumor with poor prognosis and lack of effective treatment targets is the major challenge in treating HCC. Previous studies have revealed significant changes in spliceosome-related genes in HCC. The unique expression pattern in tumor cells makes oncofetal proteins ideal candidate targets for cancer diagnosis and treatment. Therefore, we focused on the differentially expressed splicing factors in embryonic liver development and HCC. We ide...
Source: GEO: Gene Expression Omnibus - September 1, 2023 Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Homo sapiens Source Type: research
Toll-interacting protein may affect doxorubicin resistance in hepatocellular carcinoma cell lines
CONCLUSIONS: Our results showed for the first time that silencing TOLLIP in hepatocellular carcinoma cells may help sensitize these cells to doxorubicin and increase the efficacy of chemotherapeutic regimens where doxorubicin is used.PMID:37644370 | DOI:10.1007/s11033-023-08737-2
Source: Molecular Biology Reports - August 29, 2023 Category: Molecular Biology Authors: Ayse Banu Demir Elif Baris Umay Bengi Kaner Hani Alotaibi Nese Atabey Ahmet Koc Source Type: research
